Freedman RR, Baer RP, and Mayes MD. Blockade of vasospastic attacks by 2-adrenergic but not 1- adrenergic antagonists in idiopathic Raynaud's disease. Circulation 92: 1448–1451, 1995.Abstract/Free Full Text
annals.org
Kahaleh MB, Osborn I, LeRoy EC. Elevated levels of circulating platelet aggregates and beta-thromboglobulin in scleroderma. Ann Intern Med 1982;96:610–3.Full Text
bg.ac.rs
med.bg.ac.rs
Doc Doc. dr Aleksandar Milovanović BUKA I VIBRACIJE, nastavni sadrzaj iz medicine rada, Medicinski fakultet u Beogradu [1]
dermnetnz.org
Bakst R, Merola JF, Franks AG Jr, Sanchez M. Raynaud's phenomenon: pathogenesis and management. J Am Acad Dermatol. 2008 Oct;59(4):633-53.DermNet NZ.
informahealthcare.com
Lau CS, McLaren M, Saniabadi A, Belch JJ. Increased whole blood platelet aggregation in patients with Raynaud's phenomenon with or without systemic sclerosis. Scand J Rheumatol. 1993;22(3):97-101. Full Text
medscape.com
emedicine.medscape.com
Anita Narayanan, Jeffrey R Lisse, Mayra Oberto-Medina, Raynaud Phenomenon-Frequency Jun 3, 2009 eMedicine
Raynaud Phenomenon: Treatment & Medication, Treatment, Surgical Care, na eMedicine
Berlin AL, Pehr K (March 2004). "Coexistence of erythromelalgia and Raynaud's phenomenon". Journal of the American Academy of Dermatology 50 (3): 456–60. doi:10.1016/S0190-9622(03)02121-2. PMID14988692
ncbi.nlm.nih.gov
Herrick AL, Illingworth K, Blann A, Hay CR, Hollis S, Jayson MI. Von Willebrand factor, thrombomodulin, thromboxane, beta-thromboglobulin and markers of fibrinolysis in primary Raynaud's phenomenon and systemic sclerosis. Ann Rheum Dis. Feb 1996;55(2):122-7. Full Text.
P J van der Starre and C Solinas Ketanserin in the treatment of protamine-induced pulmonary hypertension. Tex Heart Inst J. 1996; 23(4): 301–304. PMCID: PMC325377 Abstract/FREE Full Text
oxfordjournals.org
rheumatology.oxfordjournals.org
Herrick AL. Pathogenesis of Raynaud's phenomenon. Rheumatology (Oxford). May 2005;44(5):587-96.. Full Text.
Coleiro B, Marshall SE, Denton CP et al. Treatment of Raynaud's phenomenon with the selective serotonin reuptake inhibitor fluoxetine. Rheumatology 2001;40:1038–43.Abstract/FREE Full Text
Maddison P. Prevention of vascular damage in scleroderma with angiotensin-converting enzyme (ACE) inhibition. Rheumatology 2002;41:965–71.Abstract/FREE Full Text
Rajagopalan S, Pfenninger D, Kehrer C, Chakrabarti A, Somers E, Pavlic R. Increased asymmetric dimethylarginine and endothelin 1 levels in secondary Raynaud's phenomenon: implications for vascular dysfunction and progression of disease. Arthritis Rheum. Jul 2003;48(7):1992-2000. Full Text.
